Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Review article
Kolovos et al
Quality assessment
The validity of the studies was assessed following the guidelines
provided by the Cochrane Collaborations tool for assessing risk
of bias.18 Risk of bias was examined in four domains: random
sequence generation, allocation concealment, blinding (masking)
of outcome assessment and intention-to-treat analysis. Two
authors (S.K. and A.K.) conducted the assessment. Disagreements
between the two reviewers were resolved by discussion until
consensus was reached.
Statistical analysis
For the univariate analyses we used the Comprehensive MetaAnalysis (CMA) software package.19 For the multivariate analyses
we used the metareg module within Stata,20 because these analyses
cannot be performed with CMA. We calculated the effect size
following the procedure described by Hedges & Olkin to correct
for small sample size bias.21 We estimated the pooled effect sizes
using the random effects model to account for heterogeneity
among studies.22 Heterogeneity was examined with the I 2 statistic,
where a value of 25% determines low heterogeneity, 50%
moderate heterogeneity and 75% high heterogeneity.23 We further
calculated the 95% confidence intervals around I 2 statistic,24 by
using the non-central w2-based approach within the heterogi
module for Stata.25 Finally, publication bias was examined by
visual inspection of the funnel plot and by implementing Duval
& Tweedies trim and fill procedure, which is a test of symmetry
of the funnel plot. In addition, the method developed by Duval
& Tweedie yields an adjusted pooled effect size after accounting
for missing studies due to publication bias.26 We conducted a
number of subgroup analyses to identify potential moderators
of the outcome using the mixed effects model, in which studies
within the subgroups are pooled with the random effects model
and the tests for significant differences between the subgroups
are carried out with the fixed effects model.27 Subgroup analyses
were performed when at least three studies were available for each
group. Moreover, we conducted sensitivity analyses because a
number of studies compared more than one experimental group
with the same control condition, and therefore the assumption
of independency was violated. In the sensitivity analyses we first
included the largest effect size for each study and then the lowest
effect size for each study.
We used univariate and multivariate meta-regression analyses to
examine the relationship between changes in QoL and depressive
symptom severity. The meta-regressions were undertaken using
the mixed effects model.28 For the univariate meta-regressions
the effect size of QoL was set as the dependent variable and
the effect size of depressive symptom severity as the predictor.
For the multivariate meta-regressions a number of potential
confounder variables were added simultaneously as predictors
alongside the effect size for depressive symptoms.
Results
The databases search resulted in 20 461 titles. We retrieved the full
text of 1764 studies, from which 44 studies were included in this
meta-analysis (Fig. 1).
Study characteristics
The 44 studies included in total 5264 patients: 2907 in the intervention group and 2357 in the control group (see online Table
DS1). More specifically, the meta-analysis of global QoL included
27 studies with 2448 patients, the meta-analysis of the mental
health component included 18 studies with 2463 patients and
that of the physical health component included 13 studies with
1561 patients. Psychotherapies that could be clustered in the
cognitivebehavioural group (i.e. cognitivebehavioural therapy,
mindfulness-based cognitive therapy and coping with depression)
were provided in 25 studies (56%). Life review was offered in five
studies (14%), problem-solving treatment in three studies (8%),
acceptance and commitment therapy in three studies (8%) and
interpersonal psychotherapy in two studies (5%). Care as usual
was the most common control condition and was included in
20 studies (45%). It consisted mainly of psychotherapy, antidepressant medication or combination treatments, but was only
superficially described in the published papers. Therefore, we
did not have enough information to cluster usual treatments
based on their modality. Waiting-list groups were included in 17
studies (39%). Other types of control conditions were included
in 7 studies (16%), and consisted of discussion groups, psychoeducation, a 20 min educational video or placebo pill. The mean
number of treatment sessions was 10 (median 9, range 125).
References identified
20 461
(PubMed 5191, PsycINFO 3532,
EMBASE 6768, Cochrane 4970)
6
After removal of duplicates
14 565
Excluded: 1720
No random assignment 57
Studies with adolescents 74
Duplicate studies 271
Maintenance trial 97
No psychotherapy 220
No control group 242
No relevant outcome 516
Other reason 243
Publications retrieved
1764
Power calculation
7
6
Included studies
44
Fig. 1
Study selection.
All the quality criteria were met by 24 studies (55%) and at least
three out of four criteria were met by 33 studies (75%). Finally, 36
studies (82%) reported a method of handling incomplete outcome
data. The characteristics of the participants varied among the
studies. Adult patients (both men and women) were included in
27 studies (61%), older adults in 11 studies (25%) and exclusively
women in six studies (14%). Eighteen studies (41%) included
participants diagnosed with major depressive disorder. Patients
with comorbid physical or mental health symptoms were included
in 15 studies (34%).
Global QoL
Thirty-one comparisons were included in the meta-analysis of
global QoL (Fig. 2). The mean effect size (Hedges g) was 0.33
(95% CI 0.240.42). We detected low between-study heterogeneity
(I 2 = 21, 95% CI 049). After adjusting for publication bias using
the trim and fill procedure the mean effect size was g = 0.30 (95%
CI 0.210.40), with three imputed studies (Table 1). Moreover,
meta-analysis including only the largest effect size of each study
resulted in an overall effect size of g = 0.35 (95% CI 0.250.45).
When only the smallest effect size was included the pooled effect
size was g = 0.34 (95% CI 0.240.45). We also calculated the effect
sizes separately for scores on the Quality of Life Inventory (QOLI;
g = 0.32, 95% CI 0.150.48) and the EuroQol EQ-5D (g = 0.19,
95% CI 0.070.32). Studies including people with major
depressive disorder resulted in larger effect sizes (g = 0.49, 95%
Study
0.32
Andersson (2005)41
0.16
Barlow (1986)42
1.00
Berger (2011)44
0.35
Burns (2013)45
0.02
Carlbring (2013)46
0.81
Chiesa (2012)47
Dekker (2012)49
0.36
0.66
Dindo (2012)50
0.45
Duarte (2009)53
Folke (2012)55
0.50
Hoifodt (2013)54
0.69
0.59
Johansson (2012)62
Johansson (2012) CBTst61
0.30
Johansson (2012) CBTtai61
0.25
Kessler (2009)63
0.33
King (2000) CBT64
0.02
King (2000) SUP64
0.12
Korte (2012)65
0.01
Pot (2010)68
0.18
Preschi (2012)70
70.00
Rohricht (2013)71
0.27
Savard (2006)72
70.00
Serfaty (2009)73
0.17
Serrano (2004)74
0.74
Serrano (2012)75
0.52
Snarski (2011)84
70.04
Vernmark (2010) CBTem78
0.39
Vernmark (2010) CBTsh78
0.49
Warmerdam (2008) CBT79
0.37
Warmerdam (2008) PST79
0.37
Wong (2008)81
0.61
Total
0.33
95% CI
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
to
0.14
0.59
0.00
0.33
0.94
0.10
0.24
0.04
0.04
0.14
0.00
0.01
0.18
0.27
0.02
0.89
0.47
0.92
0.25
1.00
0.50
0.99
0.37
0.02
0.27
0.90
0.13
0.07
0.06
0.07
0.00
0.00
70.11
70.42
0.43
70.36
70.42
70.17
70.24
0.03
0.03
70.17
0.30
0.17
70.14
70.19
0.05
70.32
70.21
70.26
70.12
70.65
70.52
70.64
70.19
0.14
70.40
70.76
70.12
70.04
70.01
70.02
0.38
0.25
0.75
0.73
1.58
1.07
0.45
1.78
0.97
1.30
0.88
1.17
1.08
1.00
0.74
0.69
0.62
0.37
0.46
0.29
0.47
0.64
1.07
0.63
0.52
1.35
1.44
0.67
0.91
1.01
0.75
0.76
0.83
0.41
72.00
71.00
Favours control
0.00
1.00
2.00
Favours psychotherapy
Fig. 2 Standardised effect sizes (Hedges g) of psychotherapy for depression compared with control conditions on global quality of life.
CBT, cognitivebehavioural therapy (em, email therapy; sh, guided self-help; st, standard treatment; tai, tailored treatment); PST, problemsolving therapy; SUP, supportive therapy.
Kolovos et al
Table 1
Global quality of life: effect sizes in meta-analysis of studies comparing psychotherapy with a control group
Comparison
All studies
Adjusted values
Effect size for depression
Adjusted values
One effect size per study (highest)
One effect size per study (lowest)
QOLI
EQ-5D
Subgroup analyses
MDD
Yes
No
Comorbidity
Yes
No
Control group
Care as usual
Waiting list
Other
Intent-to-treat analysis
Yes
No
Treatment type
Individual
Group
Internet-based treatment
Yes
No
Target group
Adults in general
Older adults
CBT v. other
CBT
Other
Life review v. other
Life review
Other
Heterogeneityb
Effect size
Number of
comparisons
95% CI
I2
95% CI
31
34
31
36
27
27
8
8
0.33***
0.30
0.60***
0.54
0.35***
0.34***
0.32***
0.19**
0.240.42
0.210.40
0.500.70
0.440.64
0.250.45
0.240.45
0.150.48
0.070.32
21
049
32
056
25
28
0
0
053
055
056
056
15
16
0.49***
0.23***
0.360.61
0.130.34
0
6
046
048
0.002
10
21
0.23**
0.37***
0.080.38
0.260.49
0
31
053
059
0.148
10
14
7
0.18**
0.42***
0.33***
0.050.32
0.280.56
0.160.50
1
23
0
053
059
058
0.053
27
4
0.34***
0.32*
0.240.43
0.030.60
25
5
053
069
0.895
10
8
0.17*
0.35**
0.010.33
0.130.57
0
52
053
077
0.258
12
19
0.41***
0.27***
0.280.53
0.150.40
3
26
051
057
0.331
23
8
0.39***
0.15
0.290.49
70.000.30
11
0
047
056
0.009
20
11
0.36***
0.28***
0.250.47
0.130.44
21
18
054
060
0.429
5
26
0.19
0.37***
70.050.42
0.260.43
27
11
073
045
0.171
CBT, cognitivebehavioural therapy; MDD, major depressive disorder; QoL, quality of life; QOLI, Quality of Life Inventory.
a. The data presented here are from analysis using the random effects model.
b. Variance between studies as a proportion of the total variance; heterogeneity tested using the I 2 statistic.
*P50.05, **P50.01, ***P50.001.
Table 2 Mental health component of quality of life: effect sizes in meta-analysis of studies comparing psychotherapy with a
control group
Comparison
All studies
Adjusted values
Effect size for depression
Adjusted values
One effect size per study (highest)
One effect size per study (lowest)
Subgroup analyses
MDD
Yes
No
Comorbidity
Yes
No
Control group
Care as usual
Waiting list
Target group
Adults in general
Women
Older adults
CBT v. other
CBT
Other
Heterogeneityb
Effect size
Number of
comparisons
95% CI
I2
95% CI
21
26
20
24
18
18
0.42***
0.37
0.48***
0.41
0.43***
0.40***
0.330.51
0.280.47
0.360.60
0.280.54
0.320.53
0.310.50
23
054
55
1772
29
17
059
053
6
15
0.49***
0.39***
0.340.64
0.280.50
0
34
061
063
0.277
7
14
0.34**
0.43***
0.120.56
0.350.52
46
1
076
048
0.428
13
7
0.38***
0.48***
0.250.51
0.360.61
37
0
066
058
0.242
13
4
4
0.43***
0.54**
0.29**
0.330.53
0.180.90
0.090.48
24
37
4
060
078
069
0.350
13
8
0.40***
0.45***
0.280.53
0.330.57
35
0
065
056
0.585
Table 3 Physical health component of quality of life: effect sizes in meta-analysis of studies comparing psychotherapy with a
control group
Comparisona
All studies
Outlier removedc
Adjusted values
Effect size for depression
Adjusted values
One effect size per study
Highest
Lowest
Subgroup analyses
MDD
Yes
No
Comorbidity
Yes
No
Treatment type
Individual
Group
Target group
Adults in general
Women
Older adults
CBT v. other
CBT
Other
Heterogeneityb
Effect size
Number of
comparisons
95% CI
I2
95% CI
14
13
15
14
17
0.27**
0.16**
0.13
0.52***
0.44
0.070.46
0.050.27
0.010.25
0.380.66
0.280.59
70
4
4181
049
38
066
12
12
0.16
0.16
0.040.28
0.040.27
18
16
058
057
4
9
0.11
0.19**
70.110.32
0.050.32
13
18
072
062
0.528
6
7
0.18*
0.15
0.020.33
70.020.33
13
22
066
067
0.843
10
3
0.17*
0.18
0.030.31
70.070.43
32
0
066
090
0.934
7
3
3
0.16*
0.07
0.16
0.040.28
70.490.62
70.050.36
0
65
0
058
088
072
0.952
10
3
0.18**
0.12
0.070.30
70.180.41
1
46
053
084
0.700
Kolovos et al
1.2
Hedges g
1.0
0.8
0.6
Discussion
0.4
0.2
0
0.2
0.4
0.6
0.8
Study characteristics predicting the effect size of quality of life: multivariate meta-regression
B
s.e.
Global component
Depression effect size
Number of sessions
Target group: adults v. elderly
Control group: care as usual v. waiting list
Control group: other v. waiting list
CBT v. other
Life review v. other
MDD
Comorbidity
Internet-based treatment
Constant
0.37
70.01
0.00
70.05
0.03
0.00
70.23
0.12
70.22
70.11
0.34
70.11
70.05
70.48
70.34
70.26
70.24
70.71
70.08
70.53
70.38
70.17
to
to
to
to
to
to
to
to
to
to
to
0.85
0.02
0.48
0.24
0.28
0.22
0.25
0.32
0.08
0.15
0.85
0.23
0.02
0.23
0.14
0.13
0.11
0.23
0.11
0.15
0.13
0.24
0.122
0.380
0.999
0.732
0.824
0.994
0.326
0.272
0.143
0.370
0.177
0.50
70.01
0.07
0.22
0.03
0.18
70.06
0.21
0.16
70.04
70.24
70.27
70.23
70.17
70.30
70.15
to
to
to
to
to
to
to
to
0.83
0.02
0.38
0.70
0.20
0.22
0.17
0.57
0.15
0.01
0.14
0.22
0.09
0.18
0.11
0.17
0.007
0.466
0.621
0.345
0.783
0.319
0.580
0.223
0.34
0.01
70.18
70.29
70.06
70.05
0.05
70.04
0.07
71.05
70.30
72.12
71.66
71.25
71.08
71.61
70.91
73.54
to
to
to
to
to
to
to
to
to
1.73
0.25
1.17
1.07
1.14
0.99
1.71
0.84
3.68
0.50
0.09
0.70
0.49
0.43
0.37
0.60
0.32
1.30
0.535
0.902
0.815
0.587
0.903
0.902
0.935
0.912
0.980
95% CI
Acknowledgements
We thank Eirini Karyotaki, David Turner and Erica Weitz for their contribution in various
parts of this meta-analysis.
References
1
Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major
depressive disorder: results from the National Epidemiologic Survey on
Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62: 1097106.
Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies
of mood disorders: a systematic review of the literature. Can J Psychiatry
2004; 49: 12438.
Kolovos et al
32 Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre P. The
burden of mental disorders. Epidemiol Rev 2008; 30: 114.
6 Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA,
et al. The economic burden of depression in the United States: how did it
change between 1990 and 2000? J Clin Psychiatry 2003; 64: 146575.
35 Berlim M, Fleck MA. Quality of life and major depression. In Quality of Life
Impairment in Schizophrenia, Mood and Anxiety Disorders (eds M Ritsner,
AG Awad): 24152. Springer Netherlands, 2007.
36 Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin
Psychol 2009; 5: 36389.
37 Rejeski WJ, Mihalko SL. Physical activity and quality of life in older adults.
J Gerontol A Biol Sci Med Sci 2001; 56: 2335.
38 Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomized trials. Ann Intern Med
2010; 152: 72632.
39 Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin
Epidemiol 2000; 53: 111929.
40 Cuijpers P, Hollon SD, van Straten A, Bockting C, Berking M, Andersson G.
Does cognitive behaviour therapy have an enduring effect that is superior to
keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ
Open 2013; 3: e002542.
41 Andersson G, Bergstrom J, Hollandare F, Carlbring P, Kaldo V, Ekselius L.
Internet-based self-help for depression: randomised controlled trial. Br J
Psychiatry 2005; 187: 45661.
42 Barlow JP. A Group Treatment for Depression in the Elderly. University of
Houston, 1986.
43 Beeber LS, Holditch-Davis D, Perreira K, Schwartz TA, Lewis V, Blanchard H,
et al. Short-term in-home intervention reduces depressive symptoms in early
Head Start Latina mothers of infants and toddlers. Res Nurs Health 2010; 33:
6076.
44 Berger T, Hammerli K, Gubser N, Andersson G, Caspar F. Internet-based
treatment of depression: a randomized controlled trial comparing guided
with unguided self-help. Cogn Behav Ther 2011; 40: 25166.
45 Burns A, OMahen H, Baxter H, Bennert K, Wiles N, Ramchandani P, et al.
A pilot randomised controlled trial of cognitive behavioural therapy for
antenatal depression. BMC Psychiatry 2013; 13: 33.
46 Carlbring P, Hagglund M, Luthstrom A, Dahlin M, Kadowaki A, Vernmark K,
et al. Internet-based behavioral activation and acceptance-based treatment
for depression: a randomized controlled trial. J Affect Disord 2013; 148:
3317.
47 Chiesa A, Mandelli L, Serretti A. Mindfulness-based cognitive therapy versus
psycho-education for patients with major depression who did not achieve
remission following antidepressant treatment: a preliminary analysis. J Altern
Complement Med 2012; 18: 75660.
48 Cramer H, Salisbury C, Conrad J, Eldred J, Araya R. Group cognitive
behavioural therapy for women with depression: pilot and feasibility study
for a randomised controlled trial using mixed methods. BMC Psychiatry 2011;
11: 82.
49 Dekker RL, Moser DK, Peden AR, Lennie TA. Cognitive therapy improves
three-month outcomes in hospitalized patients with heart failure. J Card Fail
2012; 18: 1020.
50 Dindo L, Recober A, Marchman JN, Turvey C, OHara MW. One-day behavioral
treatment for patients with comorbid depression and migraine: a pilot study.
Behav Res Ther 2012; 50: 53743.
51 Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, et al. Cognitivebehavioral therapy for depression in Parkinsons disease: a randomized,
controlled trial. Am J Psychiatry 2011; 168: 106674.
52 Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V, et al.
Problem solving treatment and group psychoeducation for depression:
multicentre randomised controlled trial. Outcomes of Depression
International Network (ODIN) Group. BMJ 2000; 321: 14504.
29 Cohen J. Statistical power analysis. Curr Dir Psychol Sci 1992; 1: 98101.
56 Freedland KE, Skala JA, Carney RM, Rubin EH, Lustman PJ, Davila-Roman VG,
et al. Treatment of depression after coronary artery bypass surgery: a
randomized controlled trial. Arch Gen Psychiatry 2009; 66: 38796.
69 Pots WT, Meulenbeek PA, Veehof MM, Klungers J, Bohlmeijer ET. The efficacy
of mindfulness-based cognitive therapy as a public mental health
intervention for adults with mild to moderate depressive symptomatology: a
randomized controlled trial. PLoS One 2014; 9: e109789.
Search strings for PubMed (the search regards the update of the database as described
in the manuscript):
Search (("Affective Symptoms"[MESH] OR "depression"[MESH] OR "mood disorders"[MESH] AND
"randomized controlled trial") AND Clinical Trial[ptyp] AND ( "2013/01/01"[PDat] :
"2014/12/31"[PDat] ) AND Humans[Mesh] AND adult[MeSH])
Filters: Publication date from 2013/01/01 to 2014/12/31; Humans; Adult: 19+ years
Table DS1 Study characteristics
First author,
year
Andersson,
Format
GSH
Target group
Adults
Sessions
5
41
2005
Intervention;
b
control (n)
CBT+DG (36);
HR-QoL
GRP
Older adults
42
1986
REM (22); WL
Trial
Country
measures
measures
quality
QOLI
MADRS;
+++
SW
DG (49)
Barlow,
Depression
c
BDI
LSI
CES-D
USA
SF-12
CES-D
+++
USA
WHOQOL
BDI-II
++++
SL+GE
EQ-5D
EPDS;
+++
UK
++++
SW
(23)
Beeber,
GSH
Women
16
43
2010
Berger,
GSH
44
2011
Adults with
10
MDD
45
Burns, 2013
IND
Women
CBT (25);
WL(26)
12
CBT (16);
CAU (13)
Carlbring,
GSH
46
2013
Adults with
MDD
Chiesa,
GRP
47
2012
Adults with
GRP
Women
QOLI
(40)
8
MDD
Cramer,
BAT (40); WL
PHQ-9
MBCT (9); PE
BDI-II;
MADRS
PGWBI
HRSD
+++
IT
SF-12
PHQ-9
++++
UK
MLHFQ
BDI-II
++++
US
SF-36
HRSD;
US
(7)
12
48
2011
CBT (48);
CAU (19)
Dekker,
GSH
49
2012
Adults with
MDD and
CBT (20);
CAU (21)
heart failure
50
Dindo, 2012
GRP
Adults with
MDD and
ACT (31); WL
(14)
IDAS-D
migraine
Dobkin,
IND
51
2011
Adults with
10
Parkinsons
CBT (41);
SF-36
HRSD; BDI
++++
US
SF-36
BDI
++++
UK
CAU (39)
disease
Dowrick,
52
2000
GRP;
GSH
Adults
12; 6
CWD (80);
PST (128);
CAU (139)
Duarte,
GRP
53
2009
Adults with
12
MDD and
CT (41); CAU
KDQOL-SF
BDI
++++
BR
SF-36
CES-D
++++
NL
WHOQOL
BDI
++
SF-36
HRSD; BDI
++++
SOS
HRSD; BDI
++
SF-20
CES-D;
++
(40)
haemodialysis
Fledderus,
GSH
Adults
54
2012
ACT (125);
WL (126)
55
Folke, 2012
GSH/GRP
Adults with
MDD and
ACT (18);
CAU (16)
unemployed
Freedland,
IND
56
2009
Adults with
12
coronary
(42); CAU
artery bypass
(40)
surgery
Harley,
GRP
57
2008
Adults with
16
MDD
Haringsma,
GRP
Older adults
DBT (10); WL
(9)
10
58
2006
CWD (52);
WL (58)
Hifdt,
IND/GSH
Adults
59
2013
CBT (52); WL
HRSD
EQ-5D
(54)
Hunter,
GRP
60
2012
Adults with
18
substance use
CBT (47);
BDI-II;
++
HRSD
SF-12
BDI-II
++
QOLI
BDI-II;
++++
CAU (26)
disorders
Johansson,
GSH
61
2012
Adults with
CBTst (37);
MDD and
CBTtai (36);
comorbid
DG (42)
MADRS-S
symptoms
Johansson,
GSH
62
2012
Adults with
MDD
DYN (46); DG
QOLI
(46)
BDI-II;
++++
PHQ-9;
MADRS
Kessler,
GSH
Adults
10
63
2009
64
King, 2000
65
Korte, 2012
IND
GRP
Adults with
CBT (103);
EQ-5D;
WL (91)
SF-12
comorbid
(67); CAU
anxiety
(67)
Older adults
LR (100); CAU
BDI
++++
EQ-5D
BDI
++++
EQ-5D
CES-D
++++
WHOQOL
BDI; GDS;
+++
(102)
Laidlaw,
IND
66
2008
Older adults
with MDD
Lamers,
IND
67
2010
Chronically ill
CAU (20)
6
older adults
68
Pot, 2010
69
Pots, 2014
GRP
GRP
Older adults
Mild and
CBT (20);
MPI (183);
HRSD
SF-36
BDI
++++
LR (83); EV
EQ-5D;
CES-D
+++
NL
(88)
MANSA
MBCT (76);
SF-36
CES-D
+++
NL
CAU (178)
12
11
moderate
WL (75)
depression
Preschl,
IND
Older adults
70
2012
Rhricht,
GRP
71
2013
Recurrent
20
MDD
Savard,
IND
72
2006
Women with
IND
30
2013
Women with
LSI;
BDI-II
++++
SL
(16)
WHO-5
BPT (11); WL
MANSA
HRSD
++++
UK
QLQ
HRSD; BDI
+++
CA
SF-36
HRSD
++++
GE
EQ-5D
BDI-II
++++
UK
LSI
CES-D
SP
(12)
8
breast cancer
Scheidt,
LR (20); WL
CT (21); WL
(16)
25
fibromyalgia
DYN (23);
CAU (23)
syndrome
Serfaty,
IND
Older adults
12
73
2009
CBT (64);
CAU (55)
Serrano,
IND
Older adults
74
2004
LR (20); CAU
(9)
Serrano,
IND
75
2012
Older adults
LR (23); PL (8)
LSI; QLSD
GDS
++
SP
10
EQ-5D
SCL-20
++++
UK
SF-36
BDI-II;
US
++++
NL
with MDD
Strong,
IND
76
2008
Adults with
MDD and
(92)
cancer
77
Talbot, 2011
IND
Women with
16
MDD and
HRSD
history of
sexual abuse
Vernmark,
GSH
78
2010
Adults with
MDD
CBTem (27);
QOLI
CBTsh (29);
MADRS;
BDI
WL (29)
Warmerdam,
GSH
Adults
8; 5
79
2008
Wiles, 2013
81
Wong, 2008
IND
GRP
Treatment
18
Wuthrich,
GRP
82
2013
Zilcha-Mano,
(201); CAU
depression
(209)
Adults with
10
CES-D
++++
NL
SF-12
BDI; PHQ-9
++++
UK
Older adults
Adults with
MDD
CBT (163);
Q-LES
C-BDI
+++
HK
SF-12
GDS
++++
AU
SF-36
BDI
++++
US
WL (159)
12
with anxiety
IND
CBT+CAU
resistant
MDD
2014
EQ-5D
(42); WL (63)
80
83
CBT (27); WL
(35)
20
SET (51); PL
(50)
54
a. GSH, Guided self-help via internet (except Fledderus et al); GRP, group treatment; IND, individual treatment.
b. ACT, acceptance and commitment therapy; BAT, behavioural activation treatment; BPT, body psychotherapy; CAU,
care as usual; CBT, cognitivebehavioural therapy; CT, cognitive therapy; CWD, Coping With Depression; DBT, dialectical
behaviour therapy; DG, discussion groups; DYN, psychodynamic psychotherapy; EV, educational video; IPT,
interpersonal psychotherapy; LR, life review; MBCT, mindfulness-based cognitive therapy; MPI, minimal psychological
intervention; PE, psychoeducation; PL, placebo; PST, problem solving treatment; REM, reminiscence therapy; SET,
supportive expressive therapy; SUP, supportive therapy; WL, waiting list.
c. EQ-5D, EuroQol; KDQOL-SF, Kidney Disease and Quality of Life-Short Form; LSI, Life Satisfaction Index; MANSA,
Manchester Short Assessment of Quality of Life; MLHFQ, Minnesota Living with Heart Failure Questionnaire; PGWBI,
Psychological General Well-being Index; QLQ, Quality of Life Questionnaire; Q-LES, Quality of Life Enjoyment and
Satisfaction; QOLI, Quality of Life Inventory; SF, Short-Form Health Survey; WHO-5, Well-Being Index; WHOQOL, World
Health Organization Quality of Life.
d. BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory-II; C-BDI, Beck Depression Inventory Chinese
edition; CES-D, Center for Epidemiologic Studies Depression Scale; EPDS, Edinburgh Postnatal Depression Scale; GDS,
Geriatric Depression Scale; HRSD, Hamilton Rating Scale for Depression; IDAS-D, Inventory of Anxiety and Depression
Symptoms- General Depression Scale; MADRS, Montgomerysberg Depression Rating Scale; PHQ-9, Patient Health
Questionnaire; SCL-20, Symptom Checklist Depression Scale.
e. Trial quality: intention to treat analysis, allocation concealment, blinding of outcome assessment, random sequence
generation; + low risk of bias, high risk of bias.
f. AU, Australia; BR, Brazil; CA, Canada; GE, Germany; IT, Italy; HK, Hong Kong; NL, Netherlands; SL, Switzerland; SP,
Spain; SW, Sweden; UK, United Kingdom; US, United States.
Supplementary
Material
References
Reprints/
permissions
P<P
You can respond
to this article at
Downloaded
from
Advance online articles have been peer reviewed and accepted for publication but have not yet
appeared in the paper journal (edited, typeset versions may be posted when available prior to
final publication). Advance online articles are citable and establish publication priority; they are
indexed by PubMed from initial publication. Citations to Advance online articles must include the
digital object identifier (DOIs) and date of initial publication.